logo

For the Inventor, By the Inventor

Richmond, VA, United States of America

James R Shanklin, Jr

USPTO Granted Patents = 19

Average Co-Inventor Count = 1.7

ph-index = 7

Forward Citations = 223(Granted Patents)


Company Filing History:

goldMedal17 out of 218 
 
A. H. Robins Company, Incorporated
 patents
silverMedal1 out of 1,567 
 
American Home Products Corporation
 patents
bronzeMedal1 out of 832,880 
Other
 patents

Years Active: 1982-1993

Loading Chart...
19 patents (USPTO):Explore Patents
1. 5198449 - N-substituted alpha-arylazacycloalkylmethanamines and their use as (1993-03-30),
2. 5187189 - S-aminoalkyl-s-arylsulfoximines as antiarrhythmic agents (1993-02-16),
3. 5140026 - N-aminoalkyl-S-aryl-S-alkyl (or substituted alkyl) sulfoximines as (1992-08-18),
4. 5130309 - Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant (1992-07-14),
5. 5070087 - Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) (1991-12-03),
6. 5051420 - 4-substituted-3-1H-imidazol-1-,2,5-thiadiazoles as antiarrhythmic agents (1991-09-24),
7. 4895840 - N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or (1990-01-23),
8. 4835164 - Aryloxymethyl derivatives of nitrogenous heterocyclic methanols and (1989-05-30),
9. 4812452 - 1-((aminoalkyl and aminoalkylamino) carbonyl and (1989-03-14),
10. 4812451 - 1-(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl)-.alpha.,.alpha (1989-03-14),
11. 4810703 - 1-((aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl)-alpha, (1989-03-07),
12. 4724235 - N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of (1988-02-09),
13. 4642348 - N-(amino)alkyl)-1-pyrrolidine, 1-piperidine and (1987-02-10),
14. 4597902 - N-(arylthioalkyl)-N'-(aminoalkyl)ureas (1986-07-01),
15. 4594343 - 1-[(aminoalkyl and aminoalkylamino)carbonyl and (1986-06-10),

Title: James R. Shanklin, Jr. - Innovator in Pharmaceutical Compounds

Introduction

James R. Shanklin, Jr., based in Richmond, VA, is a prominent inventor known for his substantial contributions to the field of pharmaceuticals. With a remarkable count of 19 patents to his name, Shanklin has made significant strides in developing innovative compounds aimed at addressing critical health issues.

Latest Patents

Among his latest inventions, Shanklin developed N-substituted alpha-arylazacycloalkylmethanamines, which are novel compounds utilized in treating hypertension, arrhythmias, and angina. The specific compounds are characterized by their unique formulas, where W can be azetidine, pyrrolidine, or piperidine, and Q comprises a straight-chain hydrocarbon radical of 1-4 carbons potentially containing a double bond.

Additionally, he introduced S-aminoalkyl-s-arylsulfoximines as antiarrhythmic agents. This invention outlines sulfoximines with versatile applications in treating Class II arrhythmia, where Z represents a C1-C6 alkylene and Y can encompass various chemical groups, including alkyl, arylalkyl, and carbamoyl.

Career Highlights

Shanklin's career included notable positions at companies such as A. H. Robins Company, Incorporated, where he contributed to various research and development projects. His work in the pharmaceutical sector has solidified his reputation as a skilled inventor dedicated to enhancing patient outcomes through innovative solutions.

Collaborations

Throughout his career, Shanklin has collaborated with other talented professionals, including Christopher P. Johnson, III, and James M. Wilkinson, II. These partnerships reflect the collaborative nature of innovation in the pharmaceutical industry and showcase the combined expertise brought to his research.

Conclusion

James R. Shanklin, Jr. stands as a notable figure in the realm of pharmaceutical innovation, with several patents that exemplify his commitment to healthcare advancements. His work not only contributes to scientific knowledge but also plays a crucial role in developing treatments that can significantly improve the quality of life for patients facing various health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…